Diana L. Silva-Velasco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diana L. Silva-Velasco has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Bruschi Marinho Priviero
Cardiovascular Translational Research Center, University of South Carolina, Columbia, SC 29209, USA
3 shared publications - R. Clinton Webb
Cardiovascular Translational Research Center, University of South Carolina, Columbia, SC 29209, USA
3 shared publications - David Centurión
Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de los Tenorios 235, Col. Granjas-Coapa, Del. Tlalpan, C.P. 14330 México City, Mexico
2 shared publications - Jesus H. Beltran-Ornelas
Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de Los Tenorios 235, Col. Granjas-Coapa, Alcaldía Tlalpan, C.P. 14330, Ciudad de México, Mexico
2 shared publications - Raiana dos Anjos Moraes
Cardiovascular Translational Research Center, Floyd School of Medicine, University of South Carolina, Columbia, USA
2 shared publications - Tiago Tomazini Gonçalves
Cardiovascular Translational Research Center, Floyd School of Medicine, University of South Carolina, Columbia, USA
2 shared publications
Latest Publications
- 26 May 2026
- Published by Springer Nature
Endothelial Dysfunction in Vascular Inflammation: The Role of NLRP3, NLRP10, AIM2, TLR9, and PANoptosis
Endothelial dysfunction is a hallmark of vascular inflammation and a critical step in the development of cardiovascular diseases. Recent evidence highlights the role of inflammasome factors in the inflammatory and cell death pathways that compromise endothelial homeostasis. NLRP3 and AIM2 inflammasomes drive the release of IL-1β and IL-18, amplifying vascular inflammation, while TLR9 responds to mitochondrial DNA to further potentiate endothelial secretion of inflammatory cytokines. In contrast, NLRP10 appears to act as a modulator of inflammasome activity and NF-κB signaling. Together, these sensors converge on processes such as pyroptosis, apoptosis, and necroptosis, which can integrate into PANoptosis, thereby exacerbating endothelial injury. Understanding these mechanisms offers new insights into the interplay between innate immunity and vascular dysfunction, with potential implications for therapeutic interventions.
- 26 May 2026
- Published by Springer Nature
Endothelial Dysfunction in Vascular Inflammation: The Role of NLRP3, NLRP10, AIM2, TLR9, and PANoptosis
Endothelial dysfunction is a hallmark of vascular inflammation and a critical step in the development of cardiovascular diseases. Recent evidence highlights the role of inflammasome factors in the inflammatory and cell death pathways that compromise endothelial homeostasis. NLRP3 and AIM2 inflammasomes drive the release of IL-1β and IL-18, amplifying vascular inflammation, while TLR9 responds to mitochondrial DNA to further potentiate endothelial secretion of inflammatory cytokines. In contrast, NLRP10 appears to act as a modulator of inflammasome activity and NF-κB signaling. Together, these sensors converge on processes such as pyroptosis, apoptosis, and necroptosis, which can integrate into PANoptosis, thereby exacerbating endothelial injury. Understanding these mechanisms offers new insights into the interplay between innate immunity and vascular dysfunction, with potential implications for therapeutic interventions.
- 15 February 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (6) , 816-819
miR-127-3p as a candidate biomarker for preeclampsia: what is missing for clinical use?
- 15 February 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (6) , 816-819
miR-127-3p as a candidate biomarker for preeclampsia: what is missing for clinical use?
- Open Access
- 16 November 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (11) , 1607
RhoA/Rho-Kinase Signaling in Vascular Smooth Muscle and Endothelium: Mechanistic Insights and Translational Implications in Hypertension
The small GTPase RhoA and its downstream effector Rho-kinase (ROCK) have emerged as pivotal regulators of vascular smooth muscle cell (VSMC) contraction, endothelial function, and vascular remodeling. Activation of the RhoA/ROCK pathway enhances calcium (Ca2+) sensitivity by inhibiting myosin light chain phosphatase (MLCP), thereby promoting sustained vascular tone independent of intracellular Ca2+ levels. In endothelial cells (ECs), RhoA/ROCK signaling contributes to nitric oxide (NO) dysregulation, oxidative stress, cytoskeletal reorganization, and inflammatory activation. Cumulative evidence implicates this pathway in the development and progression of hypertension and other cardiovascular diseases, where maladaptive vascular remodeling, VSMC proliferation, and endothelial dysfunction drive increased vascular resistance. Translational studies have identified ROCK inhibitors and indirect modulators such as statins as promising therapeutic strategies. This review integrates recent mechanistic insights into RhoA/ROCK regulation of vascular function with clinical and translational perspectives on targeting this pathway in hypertension.
- 16 November 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (11) , 1607
Open AccessRhoA/Rho-Kinase Signaling in Vascular Smooth Muscle and Endothelium: Mechanistic Insights and Translational Implications in Hypertension
The small GTPase RhoA and its downstream effector Rho-kinase (ROCK) have emerged as pivotal regulators of vascular smooth muscle cell (VSMC) contraction, endothelial function, and vascular remodeling. Activation of the RhoA/ROCK pathway enhances calcium (Ca2+) sensitivity by inhibiting myosin light chain phosphatase (MLCP), thereby promoting sustained vascular tone independent of intracellular Ca2+ levels. In endothelial cells (ECs), RhoA/ROCK signaling contributes to nitric oxide (NO) dysregulation, oxidative stress, cytoskeletal reorganization, and inflammatory activation. Cumulative evidence implicates this pathway in the development and progression of hypertension and other cardiovascular diseases, where maladaptive vascular remodeling, VSMC proliferation, and endothelial dysfunction drive increased vascular resistance. Translational studies have identified ROCK inhibitors and indirect modulators such as statins as promising therapeutic strategies. This review integrates recent mechanistic insights into RhoA/ROCK regulation of vascular function with clinical and translational perspectives on targeting this pathway in hypertension.
- Open Access
Polo-like Kinase 1 Activation Regulates Angiotensin II-Induced Contraction in Pudendal and Small Mesenteric Arteries from Mice
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase expressed in smooth muscle cells (SMCs), with emerging roles in regulating contraction. We hypothesize that PLK1 contributes to smooth muscle contractility in pudendal arteries (PA), small mesenteric arteries (SMA), and the corpus cavernosum (CC). Using male C57BL/6J mice, we assessed mRNA and protein expression of PLK1 in these tissues. In addition, the arteries and CC were mounted in myographs for isometric force measurement. We then investigated whether PLK1 regulates SMC contractility induced by phenylephrine (PE), U46619, and angiotensin II (Ang II) in arteries, and by PE, serotonin (5-HT), and electrical field stimulation (EFS; 1–16 Hz) in the CC, both in the presence and absence of the PLK1 inhibitor volasertib. PLK1 expression was confirmed in the SMA, PA, and CC by RT-qPCR or Western blotting. Notably, PLK1 inhibition significantly reduced Ang II-induced contraction in the PA and SMA and attenuated EFS-induced contraction at 2 and 4 Hz in the CC. In contrast, responses to PE, U46619, and 5-HT were unaffected by PLK1 inhibition. These results suggest that PLK1 selectively mediates contraction in response to Ang II and neurogenic stimuli. PLK1 may therefore represent a novel, stimulus-specific regulator of vascular and erectile smooth muscle contractility.
Open AccessPolo-like Kinase 1 Activation Regulates Angiotensin II-Induced Contraction in Pudendal and Small Mesenteric Arteries from Mice
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase expressed in smooth muscle cells (SMCs), with emerging roles in regulating contraction. We hypothesize that PLK1 contributes to smooth muscle contractility in pudendal arteries (PA), small mesenteric arteries (SMA), and the corpus cavernosum (CC). Using male C57BL/6J mice, we assessed mRNA and protein expression of PLK1 in these tissues. In addition, the arteries and CC were mounted in myographs for isometric force measurement. We then investigated whether PLK1 regulates SMC contractility induced by phenylephrine (PE), U46619, and angiotensin II (Ang II) in arteries, and by PE, serotonin (5-HT), and electrical field stimulation (EFS; 1–16 Hz) in the CC, both in the presence and absence of the PLK1 inhibitor volasertib. PLK1 expression was confirmed in the SMA, PA, and CC by RT-qPCR or Western blotting. Notably, PLK1 inhibition significantly reduced Ang II-induced contraction in the PA and SMA and attenuated EFS-induced contraction at 2 and 4 Hz in the CC. In contrast, responses to PE, U46619, and 5-HT were unaffected by PLK1 inhibition. These results suggest that PLK1 selectively mediates contraction in response to Ang II and neurogenic stimuli. PLK1 may therefore represent a novel, stimulus-specific regulator of vascular and erectile smooth muscle contractility.
- 12 December 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 963, 176266
Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS
- 12 December 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 963, 176266
Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS
- Open Access
Urinary bladder enlargement across nine rodent models of diabetes: correlations with glucose and insulin levels
The urinary bladder is markedly enlarged in the type 1 diabetes mellitus model of streptozotocin (STZ)-injected rats, but much less data exist for models of type 2 diabetes (T2DM). Diabetic polyuria has been proposed to explain bladder enlargement. We have collected data on bladder weight and blood glucose from 16 studies representing 9 distinct rodent diabetes (7 T2DM) and obesity models; some included arms with diets and/or pharmacological treatments. Data were analyzed for bladder enlargement and for correlations between bladder weight on the one and glucose levels on the other hand. Our data confirm major bladder enlargements in STZ rats, minor if any enlargement in fructose-fed rats, db/db mice and mice on a high-fat diet. For the first time we report bladder weight data on 5 other models with presence and degree of bladder enlargement being heterogeneous across models. Bladder weight was correlated with plasma glucose in some but not other models, but correlations were moderate to weak except for RIP-LMCV mice. We conclude that the presence and extent of bladder enlargement varies markedly across diabetes models, particularly TD2M models; our data do not support the idea that bladder enlargement is primarily driven by glucose levels/glucosuria.
Open AccessUrinary bladder enlargement across nine rodent models of diabetes: correlations with glucose and insulin levels
The urinary bladder is markedly enlarged in the type 1 diabetes mellitus model of streptozotocin (STZ)-injected rats, but much less data exist for models of type 2 diabetes (T2DM). Diabetic polyuria has been proposed to explain bladder enlargement. We have collected data on bladder weight and blood glucose from 16 studies representing 9 distinct rodent diabetes (7 T2DM) and obesity models; some included arms with diets and/or pharmacological treatments. Data were analyzed for bladder enlargement and for correlations between bladder weight on the one and glucose levels on the other hand. Our data confirm major bladder enlargements in STZ rats, minor if any enlargement in fructose-fed rats, db/db mice and mice on a high-fat diet. For the first time we report bladder weight data on 5 other models with presence and degree of bladder enlargement being heterogeneous across models. Bladder weight was correlated with plasma glucose in some but not other models, but correlations were moderate to weak except for RIP-LMCV mice. We conclude that the presence and extent of bladder enlargement varies markedly across diabetes models, particularly TD2M models; our data do not support the idea that bladder enlargement is primarily driven by glucose levels/glucosuria.